Go to Top
(312) 815-8986tract@tracttherapeutics.com
    TRACT Therapeutics, Inc.
    • Home
    • About
      • Management & Advisors
    • Technology Overview
      • Autoimmune Disease
      • Organ Transplantation
    • Clinical Pipeline
    • Patients
    • Investors
    • News
    • Contact
    • Home
    • About
    • Management & Advisors
    • Technology Overview
    • Organ Transplantation
    • Clinical Pipeline
    • Patients
    • Investors
    • News & Events
    • Contact

    Uncategorized

    • TRACT Therapeutics, Inc./
    • Uncategorized
    Jun 25 2016

    Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients

    Download Full Presentation

    Posted in: Uncategorized

    • Recent News

      • TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration for the Prevention of Graft Rejection Following Solid Organ Transplantation November 20, 2020
      • SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April 2018. September 1, 2019
      • Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients June 25, 2016
      • TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment June 25, 2016
      • TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection May 13, 2016

    • Categories

      • Events (2)
      • News (6)
      • Uncategorized (1)

    • Search

    © TRACT Therapeutics, Inc. 2015